HeartMate II Destination Therapy FDA Submission Ahead of Time Line
JMP Securities maintains its Market Outperform rating and $39 price target on Thoratec following the company’s announcement that it had filed an FDA approval request for the Destination Therapy indication for its HeartMate II ventricular assist device about six weeks ahead of schedule.